US survey shows health insurers change Rx medications to save money, overruling doctors' orders

2 December 2010

Up to 70% of prescription medicines scripts are changed by health insurers, denying patients the drugs their doctors prescribe, according to a survey by the Global Healthy Living Foundation, www.ghlf.org, a non-profit patient advocacy group.

According to GHLF executive director, Louis Tharp: "This disturbing finding is not a simple case of switching a brand-name drug for a generic one, a common and generally accepted practice used for many illnesses, and one GHLF supports. We found that health insurance companies throughout the USA switch one brand-name drug for another simply because the switched drug is cheaper."

Mr Tharp added: "If the drugs are identical, physicians generally have no objection, the survey found, but national medical groups have said most drugs are not identical, and switching can cause adverse reactions and poor recovery rates."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics